Navigation Links
Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
Date:11/16/2009

JAMAICA PLAIN, Mass., Nov. 16 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced it will give a presentation today at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, "Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood brain barrier and may be an attractive agent for treatment of glioblastoma" by Dr. Olaf van Tellingen, Ph.D. of The Netherlands Cancer Institute, Amsterdam, The Netherlands.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/NEM057LOGO )

Palomid 529 (P529) is a non-steroidal, synthetic, small molecule anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-tumor agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a dual TORC1/TORC2 inhibitor.

"Glioblastoma Multiforme is the most frequent primary brain tumor for which very few active drugs are available. The blood brain barrier is a major obstacle in the efficient delivery of drugs to the brain. In particular, the activities of ABC transporters such as P-glycoprotein and breast cancer-resistance protein (BCRP) are important. We were, therefore, pleased to see that Palomid 529 is only a very weak substrate of P-glycoprotein and BCRP and that high brain-to-plasma ratios were achieved following drug administration. This property makes Palomid 529 an attractive candidate for targeting this potentially important PI3K-Akt-mTOR signal transduction route in brain cancer," said Dr. Van Tellingen.

"Work form the laboratory of Dr. van Tellingen is significant in that it shows administration of P529 penetrates the brain-blood-barrier, enters the brain and is not affected by the ABC transporters -- a common problem in cancer
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
2. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... -- Whole-cell pertussis vaccines were more effective at protecting against ... outbreak, according to a new Kaiser Permanente study published ... DTwP, were available from the 1940s to 1990s, but ... the development of acellular pertussis vaccines, which are also ... United States had switched from whole-cell to ...
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
... adding Diovan to conventional therapy , , , Study ... , , BASEL,Switzerland, April 27, 2007 ... published today in The Lancet[1], show that,adding the blood ... 39% reduction in,cardiovascular events and a 40% reduction in ...
Cached Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:5/20/2013)... Adeptia Inc., a leading ... process integration solutions, today announced the availability ... solution. Version 6.0 is the only ... business processes involving data access, validation, transformation, ... interaction for real-time decision-making and exception-handling. The ...
(Date:5/20/2013)... Although many hospital intensive care units have a ... outcomes, new research suggests this may have no ... teaching hospitals in the United States and three-quarters ... in the ICU, the practice may unnecessarily increase ... with fewer resources, the study authors said. ...
(Date:5/20/2013)... NY (PRWEB) May 20, 2013 In ... of the numerous scientific accomplishments achieved at The ... group of female scientists, Advancing Women in Science ... breakfast on May 17. Scientists, educators, business and ... celebrate excellence and achievements of women in science. ...
(Date:5/20/2013)... toothpaste that transforms the sweet flavor of orange juice ... mysterious sensory phenomenon in colorful, animated detail ... award-winning Bytesize Science video series at ... scientific society, explains that the mainstay ingredients in toothpaste ... for short. When you brush your teeth, SLS produces ...
(Date:5/20/2013)... 2013) Wolters Kluwer Health is ... Wilkins (LWW) published journals won 13 ASHPE awards ... member articles and publications for editorial, design, print ... honor to be recognized year after year for ... the industry with quality, depth, and impact," said ...
Breaking Medicine News(10 mins):Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2
... of Charity Health System Bargaining in Bad Faith, ... operated throughout California by the Daughters of,Charity Health System ... Caregivers represented by SEIU United Healthcare Workers-West have been,bargaining ... But,management has refused to make any economic proposals, and ...
... WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals, a ... and inflammation, today announced that on August 14, ... stating that, for the last,30 consecutive trading days, ... market value of publicly held shares ("MVPHS") of ...
... YORK, Aug. 15 The Hereditary Disease Foundation,(HDF) ... Administration has,approved Xenazine, or tetrabenazine, for the treatment ... a major cause of disability and death in ... mere inconvenience; it can,prevent Huntington,s disease patients from ...
... Food and Drug Administration today approved tetrabenazine, the first ... treat Huntington,s disease, a fatal, inherited neurodegenerative disorder for ... eight months after an advisory panel unanimously voted to ... the disease. , The drug is already widely used ...
... in a dangerously abnormal way, a series of death signals ... research to appear in the August 15 issue of ... a way in mice to amplify the signals that tell ... that normally helps cells to avoid self-destruction. , The work, ...
... , ... London, UK (PRWEB) August 15, 2008 -- X Factor star and mother of ... [MYA Cosmetic Surgery]. The 36 year old, who is well known ... MYA and in total has lost 6 inches from her waist, 4 inches ...
Cached Medicine News:Health News:NUCRYST Receives Deficiency Notice from NASDAQ 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 3Health News:FDA approves first drug for Huntington's disease 2Health News:FDA approves first drug for Huntington's disease 3Health News:FDA approves first drug for Huntington's disease 4Health News:By amplifying cell death signals, scientists make precancerous cells self-destruct 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 3
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... when presented in convenient, steady, Tipack ... pick up directly from the rack. ... tips are loaded without manual intervention. ... security sticker. Fully autoclavable, Tipacks are ...
... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
Medicine Products: